Xeris Biopharma to Report Third Quarter 2022 Financial Results on November 9, 2022
Xeris Biopharma Holdings, Inc. (NASDAQ: XERS) announced the release of its third quarter 2022 financial results on November 9, 2022, before U.S. market open. The company will host a conference call at 8:30 a.m. ET on the same day to discuss financial and operational outcomes. Xeris focuses on innovative biopharmaceutical products, including Gvoke® for severe hypoglycemia, Keveyis® for primary periodic paralysis, and Recorlev® for Cushing’s syndrome. The company aims to extend current products to new indications and develop new therapies through proprietary formulation technologies.
- Xeris has three commercially available products addressing critical health issues.
- The company is focused on expanding its product pipeline and developing new therapies.
- None.
Conference call and webcast at
To pre-register for the conference call please use this link: https://www.netroadshow.com/events/login?show=6f095f54&confId=42439. After registering, a confirmation email will be sent, including dial-in details and a unique code for entry. The Company recommends registering a minimum of ten minutes prior to the start of the call. Following the conference call, a replay will be available until
About
Xeris (Nasdaq: XERS) is a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing differentiated and innovative products across a range of therapies. Xeris has three commercially available products: Gvoke®, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; Keveyis®, the first and only FDA-approved therapy for primary periodic paralysis; and Recorlev® for the treatment of endogenous Cushing’s syndrome. Xeris also has a pipeline of development programs to extend the current marketed products into important new indications and uses and bring new products forward using its proprietary formulation technology platforms, XeriSol™ and XeriJect™, supporting long-term product development and commercial success.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221102005070/en/
Investor Contact
Senior Vice President, Investor Relations and Corporate Communications
awey@xerispharma.com
312-736-1237
Source:
FAQ
When will Xeris Biopharma release its Q3 2022 financial results?
What time is the Xeris Biopharma Q3 2022 conference call?
What products does Xeris Biopharma commercialize?
Where can I find more information about Xeris Biopharma?
